A detailed history of China Universal Asset Management Co., Ltd. transactions in Nuvalent, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 11,417 shares of NUVL stock, worth $1.08 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares
11,417
Previous 6,945 64.39%
Holding current value
$1.08 Million
Previous $526,000 121.86%
% of portfolio
0.13%
Previous 0.08%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$67.44 - $112.17 $301,591 - $501,624
4,472 Added 64.39%
11,417 $1.17 Million
Q2 2024

Jul 19, 2024

SELL
$62.76 - $81.61 $270,934 - $352,310
-4,317 Reduced 38.33%
6,945 $526,000
Q1 2024

Apr 29, 2024

BUY
$72.35 - $88.99 $335,921 - $413,180
4,643 Added 70.15%
11,262 $846,000
Q4 2023

May 21, 2024

SELL
$42.42 - $80.28 $196,956 - $372,740
-4,643 Reduced 41.23%
6,619 $487,000
Q4 2023

Jan 23, 2024

BUY
$42.42 - $80.28 $224,486 - $424,841
5,292 Added 398.79%
6,619 $487,000
Q3 2023

May 21, 2024

BUY
$39.12 - $49.85 $25,584 - $32,601
654 Added 97.18%
1,327 $61,000
Q3 2023

Oct 30, 2023

BUY
$39.12 - $49.85 $25,584 - $32,601
654 Added 97.18%
1,327 $61,000
Q2 2023

May 21, 2024

SELL
$23.58 - $44.68 $424 - $804
-18 Reduced 2.6%
673 $28,000
Q2 2023

Jul 27, 2023

SELL
$23.58 - $44.68 $424 - $804
-18 Reduced 2.6%
673 $28,000
Q1 2023

May 21, 2024

BUY
$25.42 - $33.52 $4,397 - $5,798
173 Added 33.4%
691 $18,000
Q1 2023

Apr 27, 2023

BUY
$25.42 - $33.52 $4,397 - $5,798
173 Added 33.4%
691 $18,000
Q4 2022

May 21, 2024

SELL
$18.46 - $36.37 $198,334 - $390,759
-10,744 Reduced 95.4%
518 $15,000
Q4 2022

Jan 31, 2023

BUY
$18.46 - $36.37 $2,122 - $4,182
115 Added 28.54%
518 $15,000
Q3 2022

Oct 21, 2022

BUY
$13.55 - $19.92 $5,460 - $8,027
403 New
403 $8,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $4.08B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.